Anatara takes next step in testing its answer to US$8 billion global IBS issue
TechInvest Magazine Online
DECEMBER 20, 2019 BY STAFF WRITER
Anatara Lifesciences (ASX:ANR) has met the projected milestone to finalise a draft protocol for a human clinical trial for its GaRP dietary supplement in the treatment of irritable bowel syndrome (IBS).
CEO, Steven Lydeamore said Anatara has commenced the process of selecting a clinical research organisation (CRO) to undertake the clinical trials.
“There is a major unmet medical need and significant market opportunity for an evidence-based dietary supplement for IBS,” Mr Lydeamore said.
Click the following link for access to the full article: